BR112017017275A2 - composto, composição farmacêutica, método para o tratamento e uso do composto - Google Patents

composto, composição farmacêutica, método para o tratamento e uso do composto

Info

Publication number
BR112017017275A2
BR112017017275A2 BR112017017275A BR112017017275A BR112017017275A2 BR 112017017275 A2 BR112017017275 A2 BR 112017017275A2 BR 112017017275 A BR112017017275 A BR 112017017275A BR 112017017275 A BR112017017275 A BR 112017017275A BR 112017017275 A2 BR112017017275 A2 BR 112017017275A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
treatment
pharmaceutical composition
relates
Prior art date
Application number
BR112017017275A
Other languages
English (en)
Inventor
Rasheed Mohammed Abdul
Karbhari Shinde Anil
Bhyrapuneni Gopinadh
Kota Laxman
Bogaraju Narsimha
Jayarajan Pradeep
Nirogi Ramakrishna
Subramanian Ramkumar
Keshari Saraf Sangram
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR112017017275A2 publication Critical patent/BR112017017275A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

a presente invenção refere-se a compostos tendo a fórmula geral (i), incluindo seus estereoisômeros e seus sais farmaceuticamente aceitáveis. a presente invenção também se refere a métodos para a fabricação de tais compostos e composições farmacêuticas compreendendo tais compostos. os compostos desta invenção são úteis no tratamento de uma variedade de distúrbios que são relacionados ao receptor 5- hidroxitriptamino 4 (5-ht4).
BR112017017275A 2015-02-13 2016-01-07 composto, composição farmacêutica, método para o tratamento e uso do composto BR112017017275A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN709CH2015 2015-02-13
PCT/IN2016/000008 WO2016128990A1 (en) 2015-02-13 2016-01-07 Amide compounds as 5-ht4 receptor agonists

Publications (1)

Publication Number Publication Date
BR112017017275A2 true BR112017017275A2 (pt) 2018-04-17

Family

ID=55588327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017275A BR112017017275A2 (pt) 2015-02-13 2016-01-07 composto, composição farmacêutica, método para o tratamento e uso do composto

Country Status (29)

Country Link
US (1) US9957257B2 (pt)
EP (1) EP3265459B1 (pt)
JP (1) JP6487564B2 (pt)
KR (1) KR101966576B1 (pt)
CN (1) CN107406434B (pt)
AU (1) AU2016217461B2 (pt)
BR (1) BR112017017275A2 (pt)
CA (1) CA2975973C (pt)
CY (1) CY1121898T1 (pt)
DK (1) DK3265459T3 (pt)
EA (1) EA034618B1 (pt)
ES (1) ES2734734T3 (pt)
HR (1) HRP20191179T1 (pt)
HU (1) HUE045667T2 (pt)
IL (1) IL253848B (pt)
LT (1) LT3265459T (pt)
MA (1) MA41633B1 (pt)
MD (1) MD3265459T2 (pt)
ME (1) ME03430B (pt)
MX (1) MX368214B (pt)
NZ (1) NZ734400A (pt)
PL (1) PL3265459T3 (pt)
PT (1) PT3265459T (pt)
RS (1) RS59066B1 (pt)
SG (1) SG11201706501VA (pt)
SI (1) SI3265459T1 (pt)
TR (1) TR201909997T4 (pt)
WO (1) WO2016128990A1 (pt)
ZA (1) ZA201705292B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110818661B (zh) * 2019-12-02 2021-08-06 上海再启生物技术有限公司 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
ES2523459T3 (es) 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
WO2007010390A1 (en) 2005-07-22 2007-01-25 Pfizer Japan Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
WO2007048643A1 (en) * 2005-10-28 2007-05-03 Glaxo Group Limited Novel compound
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
US8980922B2 (en) * 2010-02-12 2015-03-17 Raqualia Pharma Inc. 5-HT4 receptor agonists for the treatment of dementia
SG183111A1 (en) 2010-02-16 2012-09-27 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
CA2823548C (en) * 2011-09-19 2015-10-27 Suven Life Sciences Limited Heteroaryl compounds as 5-ht4 receptor ligands
CA2907620C (en) * 2013-03-20 2018-03-13 Suven Life Sciences Limited 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
US9951045B2 (en) 2013-12-16 2018-04-24 Suven Life Sciences Limited Indazole compounds as 5-HT4 receptor agonists

Also Published As

Publication number Publication date
JP2018509396A (ja) 2018-04-05
MA41633A (fr) 2019-05-15
DK3265459T3 (da) 2019-07-15
EP3265459A1 (en) 2018-01-10
US9957257B2 (en) 2018-05-01
CN107406434A (zh) 2017-11-28
ES2734734T3 (es) 2019-12-11
AU2016217461B2 (en) 2018-07-05
PL3265459T3 (pl) 2019-09-30
AU2016217461A1 (en) 2017-09-14
EA034618B1 (ru) 2020-02-27
CY1121898T1 (el) 2020-10-14
KR101966576B1 (ko) 2019-04-05
JP6487564B2 (ja) 2019-03-20
CN107406434B (zh) 2020-09-11
EP3265459B1 (en) 2019-05-15
RS59066B1 (sr) 2019-09-30
KR20170117167A (ko) 2017-10-20
US20180051011A1 (en) 2018-02-22
SI3265459T1 (sl) 2019-09-30
MA41633B1 (fr) 2019-07-31
CA2975973A1 (en) 2016-08-18
MX2017010348A (es) 2018-06-07
ZA201705292B (en) 2019-06-26
MD3265459T2 (ro) 2019-09-30
TR201909997T4 (tr) 2019-07-22
LT3265459T (lt) 2019-08-26
IL253848A0 (en) 2017-09-28
EA201791829A1 (ru) 2018-05-31
IL253848B (en) 2018-01-31
CA2975973C (en) 2019-07-16
SG11201706501VA (en) 2017-09-28
PT3265459T (pt) 2019-07-17
HRP20191179T1 (hr) 2019-10-04
MX368214B (es) 2019-09-24
ME03430B (me) 2020-01-20
WO2016128990A1 (en) 2016-08-18
HUE045667T2 (hu) 2020-01-28
NZ734400A (en) 2018-03-23

Similar Documents

Publication Publication Date Title
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
BR112016016844A2 (pt) Compostos heterocíclicos
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112016013974A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2704 DE 01-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.